DURVANEI AUGUSTO MARIA

DURVANEI AUGUSTO MARIA

Página do item completo

Resultados de Busca

Agora exibindo 1 - 5 de 5

Boron neutron capture therapy induces cell cycle arrest and DNA fragmentation in murine melanoma cells
2011 - FLORES, F.F.; COELHO, P.R.P.; ARRUDA NETO, J.; MARIA, DURVANEI A.
Antitumor potential induction and free radicals production in melanoma cells by boron neutron capture therapy
2011 - FLORES, F.F.; COELHO, P.R.P.; MUNIZ, R.O.R.; SOUZA, G.S.; ARRUDA NETO, J.; MARIA, DURVANEI A.
Cell cycle arrest, extracellular matrix changes and intrinsic apoptosis in human melanoma cells are induced by boron neutron capture therapy
2013 - FAIAO FLORES, FERNANDA; COELHO, PAULO R.P.; ARRUDA NETO, JOAO D.T.; MARIA ENGLER, SILVYA S.; MARIA, DURVANEI A.
Boron Neutron Capture Therapy (BNCT) involves the selective accumulation of boron carriers in tumor tissue followed by irradiation with a thermal or epithermal neutron beam. This therapy is therefore a cellular irradiation suited to treat tumors that have infiltrated into healthy tissues. BNCT has been used clinically to treat patients with cutaneous melanomas which have a high mortality. Human normal melanocytes and melanoma cells were treated with BNCT at different boronophenylalanine concentrations for signaling pathways analysis. BNCT induced few morphological alterations in normal melanocytes, with a negligible increase in free radical production. Melanoma cells treated with BNCT showed significant extracellular matrix (ECM) changes and a significant cyclin D1 decrease, suggesting cell death by necrosis and apoptosis and cell cycle arrest, respectively. BNCT also induced a significant increase in cleaved caspase-3 and a decrease in the mitochondrial electrical potential with selectivity for melanoma cells. Normal melanocytes had no significant differences due to BNCT treatment, confirming the data from the literature regarding the selectivity of BNCT. The results from this study suggest that some signaling pathways are involved in human melanoma treatment by BNCT, such as cell cycle arrest, ECM changes and intrinsic apoptosis.
Apoptosis through Bcl-2/Bax and cleaved caspase Up-regulation in melanoma treated by boron neutron capture therapy
2013 - FAIAO FLORES, FERNANDA; COELHO, PAULO R.P.; ARRUDA NETO, JOAO D.T.; MARIA ENGLER, SILVYA S.; TIAGO, MANOELA; CAPELOZZI, VERA L.; GIOGI, RICARDO R.; MARIA, DURVANEI A.
Boron neutron capture therapy (BNCT) is a binary treatment involving selective accumulation of boron carriers in a tumor followed by irradiation with a thermal or epithermal neutron beam. The neutron capture reaction with a boron-10 nucleus yields high linear energy transfer (LET) particles, alpha and 7 Li, with a range of 5 to 9 mm. These particles can only travel very short distances and release their damaging energy directly into the cells containing the boron compound. We aimed to evaluate proliferation, apoptosis and extracellular matrix (ECM) modifications of B16F10 melanoma and normal human melanocytes after BNCT. The amounts of soluble collagen and Hsp47, indicating collagen synthesis in the ECM, as well as the cellular markers of apoptosis, were investigated. BNCT decreased proliferation, altered the ECM by decreasing collagen synthesis and induced apoptosis by regulating Bcl-2/Bax in melanoma. Additionally, BNCT also increased the levels of TNF receptor and the cleaved caspases 3, 7, 8 and 9 in melanoma. These results suggest that multiple pathways related to cell death and cell cycle arrest are involved in the treatment of melanoma by BNCT.
Boron uptake in normal melanocytes and melanoma cells and boron biodistribution study in mice bearing B16F10 melanoma for boron neutron capture therapy
2012 - FAIAO FLORES, FERNANDA; COELHO, PAULO R.P.; ARRUDA NETO, JOAO D.T.; CAMILLO, MARIA A.P.; MARIA ENGLER, SILVYA; RICI, ROSE E.G.; SARKIS, JORGE E.S.; MARIA, DURVANEI A.